Journal ArticleDOI
Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial
Reads0
Chats0
TLDR
Locally injected eASCs appear to be a simple, safe, and beneficial therapy for perianal fistula in Crohn’s disease patients, and additional studies are needed to further confirm the efficacy of the eASC.Abstract:
Purpose
The management of perianal fistula in patients with Crohn’s disease is an extremely challenging medical problem as many fistulas do not respond to available treatments The objectives were to assess the safety and efficacy of a suspension of expanded adipose-derived allogeneic mesenchymal stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s diseaseread more
Citations
More filters
Journal ArticleDOI
Adipose mesenchymal stromal cell function is not affected by methotrexate and azathioprine.
Mancheño-CorvoPablo,FranquesaMarcella,de la RosaOlga,RamírezCristina,García-BenzaquénLeyre,FernándezVanessa,MentaRamón,BerazaAitor,DalemansWilfried,J HoogduijnMartin,LombardoEleuterio +10 more
TL;DR: The drugs did not affect the viability and proliferative capacity of ASCs and when the drugs and the ASCs were concomitantly used to inhibit lymphocyte proliferation, no synergistic or antagonizing inhibitor was found.
Journal ArticleDOI
Efficacy and Safety of Treatment of Complex Idiopathic Fistula-in-Ano Using Autologous Centrifuged Adipose Tissue Containing Progenitor Cells: A Randomized Controlled Trial.
Simona Ascanelli,Paolo Zamboni,Diana Campioni,Maria Grazia Sibilla,Laura Chimisso,Ilaria Zollino,Giorgia Valpiani,Paolo Carcoforo +7 more
TL;DR: In this paper, the authors evaluated the efficacy and safety of the use of autologous centrifuged adipose tissue in the healing process of cryptoglandular complex anal fistulas.
Book ChapterDOI
Adipose Tissue: From Energy Reservoir to a Source of Cells for Epithelial Tissue Engineering
TL;DR: The authors discuss the microenvironment where are the stem cells is the niche, adipose tissue-derived stromal cell transplant for the treatment of epithelial pathologies, wound healing, diabetic foot, and other disorders.
Journal ArticleDOI
Transplantation of adipose-derived mesenchymal stem cells in refractory crohn's disease: systematic review.
Luana Bernardi,Carlos Henrique Marques dos Santos,Verônica Assalin Zorgetto Pinheiro,Rodrigo Juliano Oliveira,Andréia Conceição Milan Brochado Antoniolli-Silva +4 more
TL;DR: Although the use of mesenchymal stem cells is promising, the transplant on the luminal region should be more investigated, as the preparation of the fistulizing tract and the location of cell transplantation involve standardized health care in most studies.
Journal ArticleDOI
Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy
Mohamed J. Saadh,M. V. Mikhailova,Soheil Rasoolzadegan,Mojgan Falaki,Roozbeh Akhavanfar,José Luis Arias Gonzáles,Amir Rigi,B. Abedi Kiasari +7 more
TL;DR: Recently, mesenchymal stem/stromal cells (MSCs) therapy has become an emerging therapeutic modality for the treatment of inflammatory bowel disease (IBD), given their immunoregulatory and pro-survival attributes as mentioned in this paper .
References
More filters
Journal ArticleDOI
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli
Massimo Di Nicola,Carmelo Carlo-Stella,Michele Magni,Marco Milanesi,Paolo Longoni,Paola Matteucci,Salvatore Grisanti,Alessandro M. Gianni +7 more
TL;DR: The data demonstrate that autologous or allogeneic BMSCs strongly suppress T-lymphocyte proliferation, this phenomenon that is triggered by both cellular as well as nonspecific mitogenic stimuli has no immunologic restriction, and T-cell inhibition is not due to induction of apoptosis and is likely due to the production of soluble factors.
Journal ArticleDOI
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands,Frank H. Anderson,Charles N. Bernstein,William Y. Chey,Brian G. Feagan,Richard N. Fedorak,Michael A. Kamm,Joshua R. Korzenik,Bret A. Lashner,Jane E. Onken,Daniel Rachmilewitz,Paul Rutgeerts,Gary Wild,Douglas C. Wolf,Paul Marsters,Suzanne Travers,Marion Blank,Sander J. H. van Deventer +17 more
TL;DR: Patients with fistulizing Crohn's disease who have a response to induction therapy with inflIXimab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.
Journal ArticleDOI
Human mesenchymal stem cells modulate B-cell functions
Anna Corcione,Federica Benvenuto,Elisa Ferretti,Debora Giunti,Valentina Cappiello,Francesco Cazzanti,Marco Risso,Francesca Gualandi,Giovanni Luigi Mancardi,Vito Pistoia,Antonio Uccelli +10 more
TL;DR: The results further support the potential therapeutic use of hMSCs in immune-mediated disorders, including those in which B cells play a major role.
Journal ArticleDOI
HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.
TL;DR: Undifferentiated and differentiated MSC do not elicit alloreactive lymphocyte proliferative responses and modulate immune responses, and the findings support that MSC can be transplantable between HLA-incompatible individuals.
Journal ArticleDOI
Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.
Mauro Krampera,Sarah Glennie,Julian Dyson,Diane Scott,R. Laylor,Elizabeth Simpson,Francesco Dazzi +6 more
TL;DR: It is suggested that MSCs physically hinder T cells from the contact with APCs in a noncognate fashion and inhibit naive and memory T-cell responses to their cognate antigens.